Click on a headline to see stories that shaped it.
Threads
Stories that evolved over the week.
8 threads
Sep 28 - Oct 2across 3 daysImpact
Congo's Ebola crisis intensifies
Ebola cases and deaths continued to rise in Congo, while the outbreak disrupted routine vaccinations and other care. Violence then destroyed treatment and transit sites, displaced thousands, and made detection, treatment, and contact tracing harder.
Measles reached a deadly 35-year peak in the United States, with Pennsylvania cases and deaths rising as officials struggled to reconcile counts. A separate outbreak in India's Balaghat district killed at least 32 children, showing how weak vaccination and limited care are amplifying the threat.
GLP-1 drugs moved further into consumer and lifestyle markets as demand created counterfeit Ozempic risks and new access concerns. Lilly's amylin combination and other amylin programs signaled an effort to extend obesity treatment beyond current GLP-1 options, while pill and pediatric use broadened the debate.
Federal health policy moved toward a consequential election test as Medicaid losses for legally present immigrants and a sharply narrowed Medicare pricing rule threatened coverage and savings. Medicare Advantage cost exposure and a proposed Part B premium payment added competing pressures on seniors and policymakers.
Chinese drug developers now account for roughly half of the global development pipeline and are attracting international partners and capital. Novartis's potential $7.8 billion deal with Abogen showed Western pharmaceutical companies increasingly relying on Chinese biotech for future therapies.
India's Supreme Court questioned steep hospital medicine markups and required-pharmacy practices on successive days. The scrutiny could lower patient costs and disclosure barriers while reducing hospital pharmacy revenue.
AI moved from a proposed clinical-trial tool into the medical billing fight as hospitals used it to code claims. Insurers warned that automated upcoding or errors could increase premiums and patient bills without improving care.
Twice-yearly lenacapavir emerged as a potentially transformative HIV prevention tool, but coverage and delivery systems will determine who benefits. The week's coverage framed access, rather than efficacy alone, as the decisive public health test.